Diatrizoate Meglumine

The dosage of Diatrizoate Meglumine is highly individualized and depends on the specific procedure, the patient's body weight, and the imaging equipment used.

• Oral Administration for GI Tract: For a standard adult examination of the upper gastrointestinal tract, the usual dose is 30 mL to 90 mL of a solution containing approximately 37% iodine. For CT scans of the abdomen, the solution is often diluted (e.g., 30 mL of concentrate mixed with 1,000 mL of water or juice) to prevent 'streak artifacts' caused by too much contrast.
• Rectal Administration (Enema): For visualization of the colon, 240 mL of a diluted solution is typically administered.
• Intravenous Urography: The standard adult dose is 30 mL to 60 mL of a 60% or 76% solution, injected rapidly into a vein.
• Angiography: Doses vary widely; for example, cerebral angiography may require 8 mL to 12 mL per injection, while aortography may require 40 mL to 60 mL.

Pediatric dosing must be calculated with extreme care, usually based on the child's weight and age.

• Oral/Rectal: For infants and children, the dose is generally 15 mL to 30 mL of a diluted solution. For very small infants, a dilution of 1 part contrast to 3 parts water is often recommended to reduce the risk of dehydration due to the high osmolarity (salt concentration) of the drug.
• Intravenous: The typical dose for excretory urography in children is 0.5 mL to 1 mL per pound of body weight, not to exceed the adult maximum.

Renal Impairment

In patients with pre-existing kidney disease (Creatinine Clearance < 60 mL/min), the risk of contrast-induced nephropathy (CIN) is significantly increased. Healthcare providers may reduce the dose, use a non-ionic (lower risk) agent instead, or ensure the patient is aggressively hydrated with IV fluids before and after the procedure.

Hepatic Impairment

No specific dose adjustments are generally required for patients with liver disease, as the drug is primarily excreted by the kidneys. However, patients with combined renal and hepatic failure are at the highest risk for toxicity.

Elderly Patients

Older adults often have age-related declines in kidney function and are more susceptible to dehydration. Providers typically use the lowest effective dose and monitor hydration status closely.

• Preparation: If taking the medication orally for a CT scan, you may be asked to drink the solution in stages (e.g., half two hours before the scan and the rest 30 minutes before).
• Fasting: Patients are often required to fast (nothing to eat or drink) for several hours before the procedure to ensure the stomach is empty and to reduce the risk of nausea.
• Hydration: It is vital to drink plenty of water before and after receiving Diatrizoate Meglumine to help the kidneys flush the iodine out of your system.
• Storage: The solution should be stored at room temperature (20°C to 25°C) and protected from light. If crystals form, the solution can be warmed gently until they disappear.

Since Diatrizoate Meglumine is typically administered by a healthcare professional in a clinical setting for a specific scheduled procedure, a missed dose is unlikely. If you miss your imaging appointment, contact your doctor immediately to reschedule. Do not attempt to take the contrast agent at home unless specifically instructed for a pre-procedure preparation.

An overdose of Diatrizoate Meglumine is a medical emergency, primarily affecting the kidneys and the cardiovascular system. Signs of overdose may include:

• Severe nausea and vomiting
• Rapid or irregular heartbeat
• Difficulty breathing
• Sudden decrease in urine output (kidney failure)
• Seizures or confusion

In the event of an overdose, treatment is supportive and may involve intensive IV hydration, monitoring of electrolytes, and in severe cases, hemodialysis to remove the contrast from the blood.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or preparation method without medical guidance.

Most patients experience mild, transient reactions during or immediately after the administration of Diatrizoate Meglumine. These are often related to the high osmolarity of the solution.

• Warmth or Flushing: A sudden sensation of heat throughout the body, particularly common during rapid intravenous injection. This usually lasts less than a minute.
• Metallic Taste: A temporary change in taste perception during or after injection.
• Nausea: A feeling of sickness in the stomach, which usually resolves quickly without treatment.
• Diarrhea (Oral use): Because the solution is highly concentrated, it can draw water into the intestines, causing loose stools shortly after ingestion.

• Vomiting: More persistent than simple nausea; may require anti-nausea medication.
• Urticaria (Hives): Itchy, raised red welts on the skin, indicating a mild allergic-like reaction.
• Dizziness: A feeling of lightheadedness, often due to a temporary drop in blood pressure.
• Headache: Mild to moderate pain following the procedure.

• Parotid Gland Swelling: Also known as 'iodide mumps,' this is a rare swelling of the salivary glands occurring days after the procedure.
• Thyroid Storm: In patients with underlying hyperthyroidism, the large dose of iodine can trigger a life-threatening surge in thyroid hormones.
• Neutropenia: A rare decrease in white blood cell counts.

> Warning: Stop the procedure (if ongoing) and call your doctor immediately or seek emergency care if you experience any of these symptoms.

• Anaphylaxis: A severe, life-threatening allergic reaction characterized by swelling of the face/throat, difficulty breathing, and a sharp drop in blood pressure.
• Contrast-Induced Nephropathy (CIN): A sudden decline in kidney function. Symptoms include decreased urination, swelling in the legs or ankles, and fatigue.
• Cardiac Arrest or Arrhythmia: Serious changes in heart rhythm or the heart stopping altogether, usually occurring in patients with pre-existing heart disease.
• Pulmonary Edema: Fluid in the lungs, which can occur if the oral solution is accidentally inhaled (aspirated) or due to heart strain.
• Seizures: Particularly in patients with a history of epilepsy or brain lesions.

Diatrizoate Meglumine is a diagnostic agent intended for single-use or short-term administration. It does not typically cause long-term side effects once it has been excreted from the body. However, if a patient develops Contrast-Induced Nephropathy, there is a risk of permanent kidney damage, especially in those with pre-existing renal disease. Additionally, repeated exposure to iodinated contrast over many years may affect thyroid function in susceptible individuals.

There are currently no FDA black box warnings for Diatrizoate Meglumine. However, the FDA requires prominent warnings regarding the risks of severe adverse reactions and the necessity of having resuscitation equipment and trained personnel immediately available during administration. The risks of intravascular use are significantly higher than those for oral or rectal use.

Report any unusual symptoms to your healthcare provider. Even mild symptoms like itching should be reported, as they can be precursors to more severe reactions.

Diatrizoate Meglumine must only be administered under the supervision of a physician experienced in the use of contrast agents. Because of the risk of severe allergic reactions, the facility must be equipped with emergency supplies (epinephrine, oxygen, IV fluids) and staff trained in advanced cardiac life support.

No FDA black box warnings for Diatrizoate Meglumine.

• Allergic Reactions / Anaphylaxis Risk: Patients with a history of asthma, hay fever, or food allergies are at a higher risk for a reaction. A 'test dose' is generally not recommended, as it does not reliably predict whether a severe reaction will occur during the full dose.
• Nephrotoxicity (Kidney Damage): The most significant risk of Diatrizoate Meglumine is Contrast-Induced Nephropathy (CIN). This is a temporary or permanent impairment of kidney function caused by the contrast agent's direct toxicity to the renal tubules and its effect on blood flow within the kidney. Risk factors include diabetes, dehydration, and pre-existing renal insufficiency.
• Cardiovascular Stress: The high osmolarity of the drug can cause a sudden shift of fluid from the tissues into the bloodstream, putting a significant strain on the heart. This is particularly dangerous for patients with congestive heart failure or pulmonary hypertension.
• Pheochromocytoma Warning: In patients with this rare adrenal gland tumor, Diatrizoate Meglumine can trigger a dangerous 'hypertensive crisis' (a sudden, severe spike in blood pressure).
• Sickle Cell Disease: Contrast agents can promote 'sickling' of red blood cells in patients who are homozygous for sickle cell disease.

Healthcare providers will typically perform the following before and after the procedure:

• Serum Creatinine/eGFR: To assess baseline kidney function.
• Vital Signs: Monitoring blood pressure, heart rate, and oxygen levels during and for at least 30-60 minutes after the injection.
• Hydration Status: Ensuring the patient is well-hydrated to protect the kidneys.

While Diatrizoate Meglumine itself does not typically cause sedation, the stress of the procedure or the occurrence of mild side effects like dizziness may impair your ability to drive. It is often recommended to have someone else drive you home after a procedure involving contrast agents.

Alcohol should be avoided for at least 24 hours before and after the procedure. Alcohol can contribute to dehydration, which significantly increases the risk of kidney damage from the contrast agent.

As a single-use diagnostic agent, there is no 'withdrawal' or 'tapering' required. However, if a patient experiences a reaction, the administration must be stopped immediately.

> Important: Discuss all your medical conditions with your healthcare provider before starting Diatrizoate Meglumine, especially if you have kidney disease, heart disease, or a history of thyroid problems.

There are no absolute drug-drug contraindications where use is strictly forbidden, but certain combinations require extreme caution.

• Intrathecal Administration: Diatrizoate Meglumine must NEVER be injected into the spinal canal (intrathecally). This can cause severe neurotoxicity, including seizures, paralysis, and death.

• Metformin: In patients with impaired kidney function, the use of contrast agents can lead to lactic acidosis (a dangerous buildup of acid in the blood) if the contrast causes kidney failure. Most guidelines recommend stopping metformin at the time of the procedure and withholding it for 48 hours until kidney function is confirmed to be normal.
• Nephrotoxic Drugs: Medications that can damage the kidneys, such as NSAIDs (ibuprofen, naproxen), aminoglycoside antibiotics (gentamicin), and certain antiviral drugs, should be avoided or used with extreme caution around the time of contrast administration to prevent cumulative kidney injury.
• Interleukin-2: Patients who have received immunotherapy with Interleukin-2 may have a higher risk of 'delayed' contrast reactions (fever, rash, flu-like symptoms) occurring hours to days after the procedure.

• Beta-Blockers: Patients taking beta-blockers (e.g., metoprolol, propranolol) may be more likely to have a severe allergic reaction, and their reaction may be more difficult to treat because beta-blockers can interfere with the effects of epinephrine.
• Diuretics (Water Pills): Drugs like furosemide can cause dehydration, which increases the risk of contrast-induced nephropathy. Providers may pause diuretics before the procedure.

• Dehydration: High-protein diets or excessive caffeine can contribute to dehydration. Patients are usually advised to stick to clear liquids or fast as directed by the radiologist.
• Dairy: For oral GI exams, dairy products should be avoided as they can interfere with the coating of the intestinal walls by the contrast medium.

• Creatine Supplements: These can artificially elevate serum creatinine levels, making it difficult for the doctor to accurately assess kidney function before the procedure.
• St. John's Wort: While no direct interaction exists, patients should inform their doctor of all supplements to ensure a complete clinical picture.

• Thyroid Function Tests: Because Diatrizoate Meglumine contains high amounts of iodine, it can interfere with thyroid uptake studies (such as radioactive iodine scans) for several weeks following administration. It may also temporarily alter blood tests for T3 and T4 levels.
• Urinalysis: The presence of contrast in the urine can cause false-positive results for urine protein or change the specific gravity (concentration) of the urine for 24 hours.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter pain relievers.

• Known Hypersensitivity to Diatrizoate Salts: Patients who have had a previous severe or anaphylactic reaction to Diatrizoate Meglumine or Diatrizoate Sodium must not receive it again. The risk of a repeat, potentially fatal reaction is extremely high.
• Intrathecal Use: As mentioned previously, this drug is not formulated for injection into the spine.
• Significant Dehydration: In patients who are severely dehydrated, the high osmolarity of the drug can cause further fluid shifts and acute renal failure. Dehydration must be corrected before administration.

These are conditions where the benefit of the imaging must be carefully weighed against the risks:

• Severe Renal Insufficiency: When the kidneys are already failing, the risk of permanent damage from contrast is high.
• Multiple Myeloma: Patients with this bone marrow cancer are at risk for 'renal precipitation' (clogging of the kidney filters) when given iodinated contrast, especially if they are dehydrated.
• Combined Renal and Hepatic Disease: This significantly impairs the body's ability to clear the drug.
• Active Hyperthyroidism: The iodine load can exacerbate the condition.
• Pregnancy: Use only if the diagnostic information is essential and cannot be obtained by other means (e.g., ultrasound).

Patients who are allergic to other iodinated contrast agents (like Iohexol or Iopamidol) may also be allergic to Diatrizoate Meglumine. While 'shellfish allergy' was historically thought to be a risk factor due to iodine, modern clinical data suggests that a shellfish allergy does not specifically increase the risk of a contrast reaction more than any other food allergy.

> Important: Your healthcare provider will evaluate your complete medical history, including any previous reactions to imaging dyes, before prescribing Diatrizoate Meglumine.

Diatrizoate Meglumine is classified as Pregnancy Category B (or C depending on the specific manufacturer and route). Animal studies have not shown a risk to the fetus, but there are no adequate, well-controlled studies in pregnant women. Iodine is known to cross the placenta and can potentially affect the fetal thyroid gland. Therefore, its use during pregnancy should be limited to cases where the diagnostic benefit clearly outweighs the potential risks to the fetus.

Diatrizoate Meglumine is excreted in human milk in very small amounts. Furthermore, the drug is poorly absorbed from the infant's gastrointestinal tract. According to the American College of Radiology (ACR), breastfeeding can usually be continued normally after receiving iodinated contrast. However, some cautious clinicians suggest expressing and discarding milk for 24 hours after the procedure if the mother is concerned.

Diatrizoate Meglumine is FDA-approved for use in children for various imaging procedures. However, infants (especially neonates) are at high risk for electrolyte imbalances and dehydration due to the high osmolarity of the solution. Doses must be carefully calculated, and the solution is almost always diluted for oral or rectal use in young children.

Patients over the age of 65 are at an increased risk for adverse effects, primarily due to the higher prevalence of underlying heart and kidney disease. The risk of contrast-induced nephropathy is significantly higher in this population. Providers should ensure adequate pre-procedure hydration and use the lowest possible dose of contrast.

This is the most critical special population. In patients with a GFR (Glomerular Filtration Rate) below 30 mL/min, Diatrizoate Meglumine should be avoided unless absolutely necessary. For those with a GFR between 30 and 60 mL/min, protective measures such as IV saline hydration (typically 1 mL/kg/hr for 12 hours before and after) are standard clinical practice.

While the liver is not the primary route of excretion, severe liver disease can affect the body's fluid balance and cardiovascular stability, potentially complicating the administration of high-osmolarity contrast agents. Close monitoring is advised.

> Important: Special populations require individualized medical assessment and often modified procedural protocols to ensure safety.

Diatrizoate Meglumine is a triiodinated, ionic, high-osmolar contrast medium (HOCM). Its molecular structure consists of a benzene ring with three iodine atoms at positions 2, 4, and 6. These iodine atoms provide the necessary radiopacity. The 'meglumine' part is a cation (positively charged ion) that increases the solubility of the diatrizoate molecule in water. When X-rays pass through the body, the iodine atoms absorb the radiation via the photoelectric effect, preventing the X-rays from reaching the film or detector, thus appearing white or 'opaque' on the resulting image.

Diatrizoate Meglumine is pharmacologically inert at diagnostic doses, meaning it does not trigger biological responses through receptor binding. Its effects are purely physical. The duration of the contrast effect depends on the route: for GI imaging, it lasts as long as the material is present in the gut; for IV urography, the peak 'nephrogram' (kidney image) occurs within 1-3 minutes of injection.

| Parameter | Value |

|---|---|

| Bioavailability | <2% (Oral), 100% (IV) |

| Protein Binding | <5% |

| Half-life | 2-3 hours (Normal Renal Function) |

| Tmax | 30-90 minutes (Oral for GI transit) |

| Metabolism | None |

| Excretion | Renal (>95%) |

• Molecular Formula: C11H9I3N2O4 · C7H17NO5
• Molecular Weight: 809.13 g/mol
• Solubility: Highly soluble in water.
• Structure: A meglumine salt of 3,5-diacetamido-2,4,6-triiodobenzoic acid.

Diatrizoate Meglumine is classified as an Ionic Iodinated Contrast Medium. It is part of the 'High-Osmolar' group because its concentration of particles in solution is significantly higher than that of human blood (approximately 5-7 times the osmolarity of plasma).